344 related articles for article (PubMed ID: 24342626)
1. Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.
Lee Y; Kim HY; Lee SH; Lim KY; Lee GK; Yun T; Han JY; Kim HT; Lee JS
Clin Lung Cancer; 2014 Mar; 15(2):145-51. PubMed ID: 24342626
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
3. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
[TBL] [Abstract][Full Text] [Related]
6. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S
Lung Cancer; 2016 May; 95():73-81. PubMed ID: 27040855
[TBL] [Abstract][Full Text] [Related]
7. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Choi YL; Ahn JS; Park K
Lung Cancer; 2013 Nov; 82(2):294-8. PubMed ID: 24035188
[TBL] [Abstract][Full Text] [Related]
10. Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma.
Hirata H; Nakamura K; Kunitake N; Shioyama Y; Sasaki T; Ohga S; Nonoshita T; Yoshitake T; Asai K; Inoue K; Nagashima A; Ono M; Honda H
Anticancer Res; 2013 Apr; 33(4):1649-55. PubMed ID: 23564810
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
Imai H; Shukuya T; Takahashi T; Fujiwara S; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Harada H; Endo M; Nakajima T; Yamamoto N
Anticancer Res; 2013 Aug; 33(8):3279-84. PubMed ID: 23898092
[TBL] [Abstract][Full Text] [Related]
12. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW
Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153
[TBL] [Abstract][Full Text] [Related]
15. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
[TBL] [Abstract][Full Text] [Related]
18. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M
Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797
[TBL] [Abstract][Full Text] [Related]
20. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]